ClinicalTrials.gg
Not yet recruitingNCT07742839CLAARITYUpdated Nov 13, 2026

CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.

An observational study in Atrial Appendage, sponsored by Edwards Lifesciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Edwards Lifesciences · Observational

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
168
Ages
18 Years and older
Sex
All
01

Study summary

CLAARITY is a prospective, observational, single-arm, multi-center, post-market US study designed to evaluate the safety and performance of the ECLIPTIS clip in a minimum of 168 participants.

Read the detailed description

Subjects in the CLAARITY study will be enrolled at up to 15 sites in the United States. The population will be subjects who will be implanted with the ECLIPTIS clip who are eligible for LAA exclusion when undergoing concomitant open-heart cardiac surgical procedure according to its labeled Instructions for Use (IFU).

02

Conditions studied

  • Atrial Appendage
03

In context

Lead sponsor

Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 17 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population includes adult candidates who require exclusion of their left atrial appendage via a surgical clip while undergoing a concomitant cardiac surgical procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • Willing and able to provide consent and comply with study follow-up requirements
  • Scheduled to undergo concomitant open-heart cardiac surgery with planned implantation of ECLIPTIS clip for LAA exclusion per IFU

Exclusion criteria

Exclusion Criteria:

  • Known \<1 year
  • Previous cardiac surgery (re-operation)
  • Prior LAA isolation attempts
  • Planned right thoracotomy approach
  • Concomitant open-heart surgery that is considered an emergency
  • Thrombus in left atrium/LAA that cannot be evacuated before placement of clip
  • Based on intraoperative evaluation, LAA is not appropriate for exclusion prior to positioning ECLIPTIS clip to the base of the LAA
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
168 participants (estimated)
Patient registry
No

Groups and cohorts

  • Edwards ECLIPTIS Left Atrial Appendage Exclusion System

    Subjects who were treated with the ECLIPTIS Left Atrial Appendage Exclusion System

    Device: Edwards ECLIPTIS Left Atrial Appendage Exclusion System

Interventions

  • DeviceEdwards ECLIPTIS Left Atrial Appendage Exclusion System

    Surgical placement of the Edwards ECLIPTIS Left Atrial Appendage Exclusion System

06

What researchers measure

Primary outcomes

  1. Percentage of participants who have device technical success

    Successful ECLIPTIS clip placement and exclusion of LAA, defined as absence of flow (0 mm) between left atrium and LAA, and \<10 mm of residual stump proximal to the clip at the time of the procedure assessed by intra-operative transesophageal echocardiogram (TEE) with Doppler.

    Time frame: Intra-operative

  2. Participant's rate of major clinically significant adverse events

    Major clinically significant adverse events related to the ECLIPTIS clip and/or ECLIPTIS clip placement procedure within 30 days: * Death * Major bleeding * Major infection * Pericardial effusion requiring intervention * Myocardial infarction requiring intervention * Stroke, systemic embolism

    Time frame: 30 days

Secondary outcomes

  1. Percentage of participants who have device technical success

    Size of any residual flow between the LA and LAA, degree of LAA involution and presence of thrombus at the LAA stump as assessed by CT angiography (CTA) at 90 day follow-up.

    Time frame: 90 days

  2. Participant's rate of major clinically significant adverse events over time

    Major clinically significant adverse events related to the ECLIPTIS clip and/or ECLIPTIS clip placement procedure annually through 3 years * Death * Major bleeding * Major infection * Pericardial effusion requiring intervention * Myocardial infarction requiring intervention * Stroke, systemic embolism

    Time frame: 90 days, 1, 2, and 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jul 2027, 7 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartEst.
Nov 30, 2026was Sep 2026
Primary completionEst.
Jul 10, 2027
CompletionEst.
Aug 29, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Nov 30, 2026
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Sep 30, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07742839
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jul 10, 2027 (estimated)
Completion
Aug 29, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Kelly Hendrickson
Contact
Kelly_Hendrickson@edwards.com
1-949-250-2500
Chris Malaisrie, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion